United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 4,000 shares of stock at an average price of $434.88, significantly reducing her ownership to just 130 shares.
• United Therapeutics reported $6.41 EPS in its last quarter, which missed analysts' expectations of $6.80, although revenue was up 11.7% year-over-year.
• Despite the sale, United Therapeutics stock increased by 1.2% on the same day, closing at $443.44, with a consensus rating of "Moderate Buy" from analysts.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the firm's stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $434.88, for a total transaction of $1,739,520.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares of the company's stock, valued at approximately $56,534.40. This trade represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Stock Up 1.2%

UTHR traded up $5.26 on Thursday, hitting $443.44. The company's stock had a trading volume of 969,615 shares, compared to its average volume of 593,636. The company's 50 day simple moving average is $350.60 and its 200-day simple moving average is $317.22. The firm has a market cap of $20.00 billion, a P/E ratio of 17.31, a price-to-earnings-growth ratio of 6.39 and a beta of 0.66. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $444.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm's quarterly revenue was up 11.7% on a year-over-year basis. During the same period last year, the business posted $5.85 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

A number of hedge funds have recently made changes to their positions in UTHR. Chung Wu Investment Group LLC bought a new stake in shares of United Therapeutics during the 2nd quarter worth $29,000. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 46 shares during the last quarter. SVB Wealth LLC bought a new stake in shares of United Therapeutics during the 1st quarter worth $32,000. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 85 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Jefferies Financial Group raised their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. UBS Group boosted their price target on shares of United Therapeutics from $560.00 to $580.00 and gave the company a "buy" rating in a research report on Monday. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Morgan Stanley reduced their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Finally, JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Ten investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $449.57.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.